Summal'y
The class II major histocompatibility complex gene HLA-DRA is expressed in B cells, activated T lymphocytes, and in antigen-presenting cells. In addition, HLA-DRA gene expression is inducible in a variety of cell types by interferon-'), (IFN-3'). Here we show that the lymphoid-specific transcription factor Oct- C lass II molecules of the MHC play a central role in the immune response by presenting processed peptides of foreign antigen to T helper cells and by participating in the thymic selection of T lymphocytes (1) . The c~ and/3 chains of the heterodimeric MHC class II molecules are encoded by genes located within the HLA-DR, -DP, and -DQ loci in human (2) , with each set ofc~ and/3 polypeptides forming a distinct class II isotype. The different class II isotypes are generally expressed coordinately, although it is clear that this is not always the case in vivo (3) (4) (5) . The expression of MHC class II molecules is ordinarily restricted to cells of the immune system, but a variety of cell types can be induced to express MHC class II molecules by several stimuli (reviewed in 6). Of these, the cytokine IFN-~/is among the most potent and well studied (7, 8) . Aberrant expression of MHC class II molecules may be important in the pathogenesis of autoimmune disorders (9, 10) while defective expression of class II molecules is the basis for a subset of severe combined immunodeficiency diseases known as the bare lymphocyte syndrome (11, 12) .
Analysis of the DNA sequence requirements for both B ceU-specific expression and IFN~ induction of the HLA genes reveal a complex organization of regulatory elements (reviewed in 6, 13) . The proximal 160 bp of MHC class II gene promoters contain conserved DNA elements called the X, Y, and Z/W/H boxes, each of which are required for transcription (14) (15) (16) (17) . The Y box is an inverted CAAT box and a number of proteins that specifically interact with it have been identified A region termed W, which contains multiple potential control elements called Z, H, V, or S, exhibits a degree of sequence conservation when the different class II MHC sequences are aligned (29) (30) (31) (32) (33) (34) ). An additional element, called J, has recently been described, which appears to be important for induction of different class II MHC genes by . In addition to these regulatory elements, which are found in all of the class II genes from mice and humans, the human DRA and DQB gene promoters contain a consensus binding site for the transcriptional activators Oct-1 and Oct-2 (14, (36) (37) (38) (39) (40) .
The proximal promoter is su~cient in directing both B cell-specific and inducible expression of class II genes in transient transfection assays. Most of the DNA-binding proteins that interact with conserved class II MHC regulatory elements in vitro are ubiquitously expressed in vivo and the status of MHC class II transcription correlates with promoter occupancy in vivo. In vivo footprinting of the DRA promoter in uninduced class II-negative HeLa cells shows little protection of conserved motifs, while the regulatory DNA elements in class II-positive B cells are fully protected (40, 41) . Induction of dass II expression by treatment of HeLa cells in IFN-7 leads to increased protection at the same sites as those protected in class II positive B cells.
The octamer binding site of the HLA-DR promoter has been shown to be required for constitutive expression in B cells but not for IFN-7 induction (16, 42) . We have confirmed these findings and we have shown that an octamer-binding site in the HLA-DQB promoter (38) , is not required for transcriptional activation. In addition, we have carried out antisense RNA experiments to show that the Oct-2A protein is required for B cell-specific expression of the endogenous HLA-DRA gene.
The high mobility group (HMG) 1 protein HMG I/Y was previously shown to be required for virus induction of the IFN-3 gene (43, 44) . HMG I/Y facilitates the binding of two distinct transcription factors, NF-gB and ATF-2, and also appears to function as an architectural component of an inducible enhancer complex. Here, we show that HMG I/Y binds to multiple sites within the HLA-DRA promoter, that HMG I/Y and Oct-2A synergize in transfection experiments and that the two proteins cooperatively bind to DNA in vitro. In addition, using antisense RNA experiments we show that HMG I/Y is required for IFN-7 induction of the HLA-DRA promoter. Thus, HMG I/Y may be involved in the assembly of two distinct transcriptional activation complexes on the HLA-DRA promoter, one for B cell-specific expression, and the other for IFN-7 inducible expression.
Materials and Methods
Cell Culture and Flow Cytometry. HeLa cells were grown in DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine, and antibiotics. Human Raji, Jijoye, and Jurkat ceUs were grown in RPMI 1640 with 10% fetal bovine serum, 2 mM gluta-1 Abbreviations used in this paper: CAT, chloramphenicol acetyl transferase; EMSA, electrophoretic mobility shift assay; HMG, high mobility group. mine, and antibiotics. For induction with IFN-7 HeLa ceils were incubated with recombinant IFN-3' (Genentech, South San Francisco, CA) at 500 U/m1 for 48 h. The following monoclonal antibodies were used for flow cytometric analysis: LB3.1 (anti-DR), B7/21 (anti-DP), and Genox 3.53 (anti-DQ). These antibodies are all of the IgG1 subclass.
Recombinant DNA and Proteins. The plasmids DRA300CAT and DQB2500CAT have been described (27) . A.S. hXBP-1 and a.s.fos, plasmids have also been previously described (28) . A.S. oct-1 and A.S. oct-2A were synthesized by subdoning the entire Oct-1 or Oct-2A cDNAs in the reverse orientation behind the CMV promoter in the pcDNA cloning vector. DRA300 mutant promoter-chloramphenicol acetyl transferase (CAT) constructs were made by subcloning the mutated promoter fragments from the Bhescript constructs (Stratagene Inc., La Jolla, CA), described under site-directed mutagenesis below, into the XbaI site of the promoterless plasmid pCATBasic (Promega Corp., Madison, WI). All constructs were confirmed by dideoxy sequencing. Escherichia coli expressed HMG I/Y protein was prepared as described (43) . Recombinant Oct-2 protein was kindly provided by M. Tanaka (Cold Spring Harbor Laboratory).
Site-directed Mutagenesis. All site-specific mutations in FIMG I/Y binding sites were generated by PCR using as template the BSDRA300 plasmid (26) . To mutagenize the octamer motif, oligos 44a:
(5'AGAGTAATTGATGGGCATTTTAATGG-3') and 44b: (5'-CCATTAAAATGCCCATCAATTACTCT-3'), with bold type denoting mutated bases, were used. For mutagenizing the AT-rich D-box region, oligos 45a:
(5'ATCTCAAAATATGGGTCTGATTGGCCA-3') and 45b: (5'-TGGCCAATCAGACCCATATTTTGAGAT-3') were used. Each of these mutagenizing oligos was used in a first PCR reaction with either the T3 or the T7 Bluescript primers. The two PCR products were purified by Geneclean II (Bin 101, La Jolla, CA), mixed in equimolar amounts and used in a third PCR reaction with the T7 and the T3 primers. The final PCR product was digested with EcoRI and HindlII and subcloned into the EcoRI-HindlII site of the Bluescript KS/+ plasmid. An additional mutant:
(5'-ATCTCCAGATATGGGTCTGATTGGCCA-3') was generated spuriously. Double mutants were generated by exploiting a unique MscI restriction site between the octamer and the D box to swap fragments between the single mutants. All mutations were confirmed by dideoxy sequencing.
Transfections and CATAssays. Jijoye and HeLa cells were transfected using lipofectamine (Gibco, Gaithersburg, MD) according to the manufacturer's instructions, while Jurkat cells were transfected using the DEAE dextran transfection method. For assessing the activity of mutant DRA promoters, Jijoye and HeLa cells were transfected with 1 #g of the mutant promoter-CAT constructs. The B galactosidase expression vector, pSV-~-gal (Promega) was included as an internal control to monitor transfection efficiency. Cell extracts were made 48 h after transfection, normalized for B-galactosidase activity, and used in CAT assays as described below. For Jurkat cells, 107 recipient cells were washed extensively with serum-free media. 20/zg of cesium chloride-purified, supercoiled plasmid DNA was added to the cells in a 1-ml vol of serum-flee RPMI 1640 containing 200 #g ofDEAE Dextran (Pharmacia Fine Chemicals, Piscataway, NJ). 5 #g of plasmid pXGHS, a mammalian expression vector encoding human growth hormone, was cotrans-
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Roles of High Mobility Group Protein I/Y and Oct-2 in HLA-DRA Transcription fected with reporter constructs to control for variability in transfection efficiency. The cells were incubated for I h at 37~ before addition of medium. 48 h after transfection, the cells were washed with serum-flee media and pelleted. The cells were resuspended in 300 #1 of 0.25 M Tris and freeze-thawed three times. After centrifugation in a microfuge to remove debris, 150 #1 of the cell extract was incubated with 20/~1 10 mM acetyl coenzyme A (Pharmacia Fine Chemicals) and 2 #1 of ["C]chloramphenicol (New England Nuclear, Boston, MA) (49 mCi/mmol, 0.1 mCi/ml) for 4 h at 37~ The chloramphenicol was then extracted with 1 ml ethyl acetate, speed vacuum dried, and spotted onto TLC plates. After the solvent front was allowed to travel three-quarters of the length of the plate, the plate was removed from the chromatography tank, allowed to dry, and subjected to autoradiography. For quantitation of CAT activity, appropriate slices of the TLC plates were analyzed by liquid scintillation counting.
Gel Retardation Analysis. Jijoye and HeLa whole-cell extracts for gel shift analysis were prepared using a modification of a protocol (45) . In brief, 3-5 • 106 cells were pelleted, washed in icecold PBS, then resuspended in 100 #1 of 20 mM Hepes, pH 7.9, 200 mM KC1, 1 mM DTT, 1 mM EDTA, 0.1 mM PMSF, 20% glycerol, and 0.1% NP-40, and incubated with periodic agitation for I h at 4~ The cells and large debris were pelleted by 10-min 14,000-rpm centrifugation in a microfuge at 4~ and the supernatant, containing proteins solubilized from both the nucleus and the cytosol in the extraction media, removed, aliquoted, quick-frozen in liquid nitrogen, and stored at -80~ For nuclear extract preparation, 500 ml of log phase cells was pelleted at 2,000 rpm for 10 min. The cell pellet was washed twice in ice-cold PBS and resuspended in 25 ml nuclear isolation buffer I (10 mM Tris-HC1, pH 7.9, 10 mM KC1, 1.5 mM MgC12, and 1 mM DTT). 0.3 ml of ice-cold 10% NP-40 was added dropwise (while vortexing at lowest setting) and incubated on ice for 20 min. The cell lysate was layered onto 12 ml of ice-cold nuclear isolation buffer I containing 1.7 M sucrose and centrifuged at 13,000 g for 15 min in an SW27 rotor (Beckman Instruments, Inc., Palo Alto, CA). Purified nuclei were then resuspended in 3 ml of ice-cold 20 mM Hepes, pH 7.9, 25% glycerol, 0.42 M NaC1, 1.5 mM MgC12, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT, and homogenized with 10 strokes of a Dounce homogenizer on ice. The suspension was then rocked for 30 rain at 4~ and centrifuged for 30 min at 25,000 g in an SS34 rotor (Beckman Instruments). The supernatant was then dialyzed against 150 ml of transcription buffer (-rNTPs): 12 mM Hepes, pH 7.9, 12% glycerol, 0.3 mM DTT, 0.12 mM EDTA, and 60 mM KC1 for 5 h. MgCI2 was omitted from those preparations to be used for gel-retardation assay, as MgC12 has been found to inhibit gel retardation. For gel-shift analysis, 32p end-labeled probes (5,000-15,000 cpm) were incubated in a 10-#1 vol with pure recombinant proteins or extracts on ice for 25 min. Binding condition for recombinant HMG I/Y was 10 mM Tris.C1 (pH 7.6), 50 mM NaC1, 5% glycerol, 1 mM EDTA, and 100 ng of poly(dG.dC). Poly(dG-dC) was always used since HMG I/Y binding is sensitive to poly(dI-dC). Octamer protein-binding reactions were in 20 mM Hepes pH 7.9, 2 mM DTT, 8% glycerol, 40 mM KC1, 0.01% NP-40, and 100-500 ng of poly(dG.dC) or poly(dI-dC). The total amounts of protein in reactions containing exogenous HMG I were kept constant by using BSA or recombinant IFN-3r. Antibody to HMG I/Y was generated as described (43) and an anti-/3gal antibody was purchased (Promega), 1 #1 antibody was used per reaction. Reactions were analyzed by electrophoresis in a nondenaturating 5% polyacrylamide gel in 0.5 x Trisbuffered EDTA. Bands were quantitated by densitometry. The Y + OCT probe has the sequence:
5'TCTCAAAATATTTTTCTGATTGGCCAAAGAGTAATT-GATTTGCATTTTAAT3', the DR~OCT oligo:
andthe DRA-ISoligo:
DNaseI Footprint Analysis. Both strands of the DRA proximal promoter were subjected to DNaseI footprint analysis using the plasmid pBSDRA300 which contains nucleotides -268 to +29 of the DKA gene inserted into the pBluescript KS vector between the HindlII and EcoRI restriction sites (26) . Strand-specific labeling was achieved by labeling after digestion with either HindlII or EcoRI, followed by complete digestion with the other restriction enzyme. The radiolabeled DRA proximal promoter was then purified by elution after gel electrophoresis and the specific activity of the fragment determined by scintillation counting. Footprinting reactions were performed in 50-/~1 binding reactions containing 10,000 cpm of purified probe with increasing amounts of recombinant HMG I protein for 30 min at room temperature. Binding reactions were carried out in a buffer containing 25 mM Hepes, pH 7.6, 50 mM NaC1, 1 mM DTT, 1 mM EDTA, 10 #g of BSA, 0.01% NP-40, and 1/~g ofpoly dG/dC as a nonspecific competitor DNA. DNA was fragmented for 1 rain in a final concentration of 4 mM MgC12 using 0.2 U of DNaseI. After 1 min, the reaction was terminated with a solution containing 2% SDS, 200 mM EDTA, and 1/zg of salmon sperm DNA. After phenol-chloroform extraction, reaction mixtures were analyzed by electrophoresis on an 8% polyacrylamide sequencing gel containing 8 M urea. A G + A sequencing ladder was also added for orientation after developing the autoradiograph.
In Vitro Transc@tion/Translation. In vitro translated Oct-1 protein was made from the pBSOct-l+ plasmid (W. Herr, Cold Spring Harbor Laboratory) using the TNT coupled rabbit reticulocyte 13,-sate system (Promega) according to the manufacturer's instructions.
Results

Differential Requirement of the Octamer-binding Protein Oct-2 for the B Cell-specific Expression of the HLA-DRA and HLA-DQB Genes. Among the human class II MHC genes, only
the HLA-DRA and HLA-DQB promoters have been found to contain an octamer-binding site (36, 38; our unpublished observations). In the DRA promoter the octamer element is located between -52 and -45 bp upstream from the start site of transcription, while the octamer element in the DQB promoter is located between -611 and -604 (see Fig. 1 A) . Previous studies have established that the octamer motif in the HLA-DRA promoter binds both Oct-1 and Oct-2 and mutations that abolish in vitro binding adversely affect expression in B cells (16, 42, 46 ; and data not shown). Since both Oct-1 and Oct-2 proteins are expressed in B cells, we were interested in determining whether one or both of these proteins are required for HLA-DRA expression. Thus, we cotransfected expression vectors that direct the synthesis of either Oct-1 or Oct-2A antisense RNA with the HLA-DRA reporter construct. While the vector encoding antisense Oct-1 RNA had no effect on either DRA or DQB promoter ac- tivity (in the B lymphoblastoid cell line Raji), the vector encoding antisense Oct-2A R N A strongly down-regulated expression of the D R A (but not the DQB) promoter in these cells (Fig. 1 B) .
To further assess the significance of the octamer-binding proteins on the transcription of the class II M H C genes, we tested the effect of antisense Oct-1 and Oct-2A R N A production on the cell-surface expression of the endogenous class II molecules in the B cell line Raji (Fig. 1 C) . Raft cells were transiently transfected with either the antisense Oct-1 or Oct-2A expression vector and then analyzed for surface class II antigen expression by flow cytometric analysis using isotypespecific monoclonal antibodies. It is important to note that cell-surface expression of any of the class II isotypes requires transcription and translation of both the ol and 3 chain genes. Therefore, a reduction in expression of either an ot or 3 chain gene at a particular locus will result in decreased cell-surface expression of that particular isotype. Significantly, Raft cells transfected with the antisense Oct-2A expression vector exhibit a specific down-modulation of H L A -D R antigen expression in a subpopulation of cells ( Fig. 1 C, subtmnel A) .
In contrast, vectors encoding antisense Oct-1 and the control antisense Zebra R N A had no effect on cell-surface expression of any of the class II isotypes.
To further characterize this phenomenon, the subpopulation of Raji cells transfected with the antisense Oct-2A expression vector (designated: H L A -D R A sort low) were purified by cell sorting and shown to express wild-type levels of H L A -D Q and -DP (Fig. 1 C, subpanel B) . Whole-cell extracts were then prepared from the sorted populations of cells transfected with antisense Oct-2A expression vector and analyzed by gel mobility shift assay for expression of the octamerbinding proteins (Fig. 1 D) . The sorted subpopulation of Raji cells expressing markedly decreased levels of cell surface HLA-DR. molecules showed reduced levels of Oct-2 protein (lanes marked Low), while the subpopulation of antisense Oct-2A expression vector transfected cells that express high levels of surface HLA-DR. retain normal levels of Oct-2 protein (lanes marked High). Thus -10) is indicated. The unlabeled arrow indicates a band seen in some preparations of induced HeLa cells, which, however, is not specific. (E) EMSA with extracts from induced HeLa cells and the DRA octamer. Antibody against HMG I/Y (~-HMG I) inhibits the formation of the fastmigrating complex labeled as HMG I/Y, while the control antibody against /3-galactosidase had no effect (~-/~Gal).
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Abdulkadir et al. gene in the B cell line Jijoye (Fig. 2 B) . On the other hand, the same mutations in the octamer-binding site had only a slight effect on the induction of the HLA-DRA promoter by IFN-7 in HeLa cells (Fig. 2 C) . While the octamer mutation almost completely abolished HLA-DRA promoter-driven CAT activity in B cells, it reduced CAT activity in HeLa cells to between 70 and 80% of wild type (Fig. 2, B HeLa cells do not normally express Oct-2 protein (46-48). We, however, wanted to investigate the possibility that Oct-2 plays a role in IFN-7-mediated induction of HLA-DRA gene expression in HeLa cells. We therefore assayed for de novo Oct-2 protein synthesis in IFN-7-treated HeLa cells by gel-shift analysis using the DRA-octamer as a probe. As shown in Fig. 2 D, we found no evidence of de novo Oct-2 synthesis in HeLa cells induced with IFN-7. This observation strongly supports the notion that induction of the DRA promoter in HeLa cells occurs via an Oct-2-independent pathway. Thus the modest effects of the octamer mutation seen on inducibility in HeLa cells is more likely to be due to the impairment of another factor, which we feel is likely to be HMG I/Y itself. In support of this model, we have observed in electrophoretic mobility shift assays (EMSA)s that a high mobility complex which forms on the DRA octamer element is enhanced when extracts from IFN-7-induced HeLa cells are used (Fig. 2 D; compare lane 2 with lane 7) . This complex appears to contain HMG I/Y or an immunologicaUy related protein as judged by its sensitivity to antisera raised against recombinant HMG I (Fig. 2 E) . This observation suggests that induction of HeLa cells with IFN-7 enhances the binding of HMG I or an HMG I-containing complex to the DRA octamer and suggests that the slight impairment in IFN-7 inducibility of the AB2CAT reporter may result from inhibition of HMG I/Y binding. (Fig. 3 A) . Six binding sites, designated A-F (Fig.  3 B) , were identified on both the coding and noncoding strands. These sites coincide with: (A) the transcription initiation site, (B) the TATA-element, (C) the octamer motif, (D) the A/T-rich region located between the X and Y boxes, and (E and F) two additional sites between -250 and -200. As would be expected from the known sequence preference of H M G I/Y, all of these binding sites are A / T rich.
The High Mobility Group Protein HMG I / Y Binds to
The two upstream sites, E and F, do not appear to be essential for H L A -D K A gene expression, since reporter constructs lacking these sites exhibit proper tissue-specific and inducible expression patterns (14, 31, 50) . To further charac-
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Abdulkadir et al. terize these binding sites, we decided to study the effects of mutations that affect H M G I/Y binding to these sites on D R A expression. Unfortunately, the effect of mutations in the A and B boxes could not be tested, since these mutations would be expected to disrupt transcriptional initiation and TATA box function, respectively. The effect of mutations in the octamer (C box) and the D box, were thus studied. We used D R A reporter constructs that contained mutations at these single sites as well as double mutants (Fig. 4 A) . These mutations abolish H M G I/Y binding in vitro, as shown in Fig. 4 B . The effects of these mutatio:~s on ]3 cells, as well as inducible expression in HeLa cells, were studied. As expected, all the constructs containing octamer mutations had severely impaired expression in B cells (Fig. 2 B , and data not shown), while the D box mutations had only modest effects on B cell-specific or inducible expression of the H L A -D R A reporter (Fig. 4 C, and data not shown) . Significantly, however, while neither the octamer mutation nor the D box mutation alone greatly impaired IFN-q,-inducible expression in HeLa cells, constructs containing mutations at both sites showed a severely reduced level of expression (Fig. 4 C) 
Oct-2A Is a Transactivator of the HLA-DRA Gene and
Cooperates with HMG I/Y. As we have shown above, the Oct-2 protein is required for constitutive expression of the DRA gene in B cells (Fig. 1) . To determine whether transfected Oct-2 expression vector can mediate activation of HLA-DRA gene expression in an Oct-2-negative, class II-negative cell line, we cotransfected the HLA-DRA300 reporter construct and an Oct-2A expression vector into either HeLa or Jurkat cells. As shown in Fig. 6 A, when increasing amounts of the Oct-2 expression vector were cotransfected with the reporter into HeLa cells, significant levels of CAT activity were observed. The reporter gene was not activated when an Oct-1 expression plasmid was cotransfected with the reporter gene. As expected, the DQB promoter, which we have shown does not require Oct-2 for its expression in B-cells (Fig. 1) , is not transactivated by overexpression of either Oct-1 or Oct-2A (Fig. 6 A) .
Expression of Oct-2A, but not Oct-l, also activated expression of the HLA-DRA reporter plasmid in the dass II-negative cell line Jurkat (Fig. 6 B) . Since HMG I/Y also 495 Abdulkadir et al.
interacts with the octamer element, we tested the effect of overexpressing this protein on DRA promoter activity in Jurkat cells. We found that overexpression of HMG I/Y alone did not increase the level of HLA-DRA promoter activity. However, coexpression of both HMG I/Y and Oct-2A resulted in a significant increase in the level of HLA-DRA promoter activity compared with the effect of overexpressing Oct-2A alone (Fig. 6 B) .
HMG I / Y Selectively Facilitates Interaction of Oct-2A with the HLA-DR Octamer Motif.
To explore the possible mechanisms by which HMG I/Y facilitates DRA transactivation by Oct-2, we carried out EMSAs to assess the effect of HMG I/Y on the binding of Oct-2 to the octamer element. Initially, we examined the effect of recombinant HMG I/Y on the assembly of nucleoprotein complexes at the octamer site from whole cell extracts. As shown in Fig. 7 A, in the presence of low protein concentrations of Jijoye extracts, the binding of the octamer factors Oct-1 and Oct-2 is undetect- To quantitate these effects, we analyzed the abundance of each complex in a representative experiment by densitometric analysis and the results presented in Fig. 7 B. These data indicate that the formation of the Oct-2A-containing complex is enhanced approximately fourfold at low concentrations of Jijoye extract. A more striking observation is that the ratio of Oct2A to Oct-1 complex formation is shifted 90-to 100-fold in favor of Oct-2A in the presence of recombinant HMG I/Y. These effects of HMG I/Y may have been due either to the direct influence of HMG I/Y itself, or might have been mediated by other factor(s) present in Jijoye extracts. To distinguish between these possibilities, we performed these experiments using recombinant Oct-1 or Oct-2 proteins. We first tested the influence ofHMG I/Y on the binding of recombinant Oct-2A. As shown in Fig. 8 A, HMG I significantly enhances the binding of Oct-2A to the HLA-DRA octamer at low Oct-2A concentrations. In sharp contrast, we found that the binding of the in vitro translated Oct-1 protein was inhibited by HMG I/Y, as we have observed with B cell-derived Oct-1 in EMSAs using crude nuclear extracts (Fig. 8  B; compare lanes 2-4 with lanes 5-7). Taken together, these data strongly suggest that HMG I/Y exerts direct and opposing effects on the interaction of Oct-1 and Oct-2 proteins with the octamer element.
Discussion
The MHC class II gene DRA is the most highly expressed of the human class II genes, and the HLA-DR molecule is the predominant restriction element for helper T cell clones (1, 50) . Aberrant or unusually high levels of expression of the class II molecules have also been implicated in the pathogenesis of various autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and insulin-dependent diabetes mellitus. The lack of expression of these molecules is the cause of the severe combined immunodeficiency disorder, bare lymphocyte syndrome. The transcriptional regulation of these genes has therefore been the focus of intense investigation (6) . These studies of the HLA-DRA promoter have led to the identification of conserved elements within the promoter and a number of DNA-binding proteins which appear to participate in the regulation of the gene (reviewed in 13).
An octamer element has been found in two human class II MHC genes: HLA-DRA and -DQB. While there have been reports that the octamer is important for the constitutive expression of DRA in B cells (31, 42) , its role in DQB expression had not been assessed. In this report, we have confirmed the role of the octamer in constitutive expression of the DRA promoter, and have shown that the octamerbinding protein Oct-2A is critical for the expression of the endogenous DRA gene. Neither Oct-1 nor Oct-2 appears to be involved in DQB transcription as assessed by our experiments. It is possible that the positioning of the element in DQB (at about -600 upstream of the transcription start site), compared with its location in the DRA promoter (where it is found just upstream of the TATA box), accounts for this observation. We cannot of course exclude the possibility that the element plays some role in DQB expression at some point during development or in a specific physiologic setting.
We have also investigated the role of another octamerbinding protein, the high mobility group protein HMG I/Y, in HLA-DRA transcription. We have found that HMG I/Y binds to six sites between -300 bp and the transcription start site of the HLA-DRA promoter. These include: two sites upstream of -200 bp, an AT-rich palindromic motif situated between the X and the Y boxes (which we term the D box), the octamer motif, the TATA box, and a site that overlaps the transcription initiation site (which we call the A box). It is of interest that some of these sites coincide with well-defined cis elements that bind either well-defined regula- I/Y containing complex under the EMSA conditions. There is indeed precedence for proteins that enhance the binding of sequence-specific transcription factors to DNA without being retained in the complex during nondenaturing electrophoresis. For instance, Phox 1 enhanced the binding of serum response factor to DNA without altering the mobility of SP, F-DNA complexes (53) . Like the DNA-bending protein, HMG-1 facilitated the binding of progesterone receptor to its target DNA without being retained in the complex (54) . HMG I and its alternatively spliced variant HMG Y (which lacks an internal stretch of 11 amino acids), are wellcharacterized chromosomal nonhistone proteins preferentially associated with active chromatin. These basic, low molecular weight proteins are expressed at high levels in rapidly dividing, undifferentiated, or neoplastically transformed cells. (Fig. 2 D) . We hypothesize that IFN-y induces posttranslational modifications in HMG I/Y that increase its affinity for the octamer element. This is reminiscent of what has been observed with the human IFN-/3 gene, where viral induction of gene expression results in the de novo binding of protein complexes to the promoter which contain HMG I/Y (44) . A requirement for posttranslational modification of HMG I/Y for its participation in gene activation would perhaps help explain the efficacy of antisense HMG I/Y RNA in inhibiting the induction of these two genes. During the early stages of these experiments we were surprised that antisense HMG I/Y RNA was an effective reagent in assessing the role of HMG I/Y in HLA-DRA gene transcription in view of the high abundance of both HMG I/Y RNA and protein in practically all mammalian cells. We hypothesize that much of the HMG I/Y found in the nucleus is in an inactive form, and that an extracellular signal such as IFN-7 might posttranslationally modify newly synthesized HMG I/Y to an active form. This modified HMG I/Y would be "active" because it (a) binds with higher affinity to DNA (as our data suggest), and/or (b) promotes protein-protein interactions more effectively than unmodified HMG I/Y. These possibilities are under active investigation in our laboratory.
The data presented in this study indicate that distinct (but largely overlapping) sets of transcription factors may be involved in DRA expression in different cell types. Class II-negative cell lines, such as HeLa and Jurkat, while containing most of the DNA-binding proteins known to interact with the promoter, do not have an active transcription complex assembled on the promoter, as assessed by in vivo footprinting (41) . Induction with IFN-7 leads to the assembly of a transcription complex on the promoter (40) . This transition could depend on the de novo synthesis or modification of critical factor(s) (which may or may not interact with DNA directly) that are critical to the formation of a functional transcription complex. Our findings suggest that HMG I/Y likely plays such a role in activation of the DRA gene by IFN-7.
In HeLa cells induced with IFN-7, HMG I/Y appears to function in DRA transcription via an Oct-2-independent pathway. Mutations in the octamer element have modest effects on the inducibility of the DRA promoter, while severely impairing constitutive expression in B cells. Furthermore, after induction of HeLa cells with IFN-7, we found no evidence of de novo Oct-2 synthesis using gel-shift assays. In contrast, IFN-7 treatment enhances the binding of HMG I/Y to the octamer element. The modest effect of the octamer mutation on IFN-~, inducibility might be due to the effect of the mutation on HMG I/Y binding. The fact that double mutations in the octamer and the D box elements result in a profound reduction in IFN-7 inducibility of the promoter suggests that at least one HMG I/Y molecule bound to either of these sites is required for induction, with occupancy of both sites allowing full activation of the gene.
Apart from the mechanisms described above, HMG I/Y may also facilitate interactions between DNA-bound factors and adapter proteins (such as the recently described class II activator, CIITA; 61), or might also participate at a step before transcription complex assembly (such as alteration of chromatin structure).
In conclusion, the data presented in this 
